Crescent Biopharma, Inc. (CBIO) — Financial statements
Income statement, balance sheet, and cash flow for Crescent Biopharma, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 11 | 0.00↓100.0% | 0.01↓86.7% | 0.08↓93.5% | 1 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 11 | 0.00↓100.0% | 0.01↓86.7% | 0.08↓93.5% | 1 | |
| Operating Expenses | ||||||
| R&D Expenses | 138↑392.1% | 28↑39.8% | 20↓29.3% | 28↓40.2% | 47 | |
| General & Administrative Expenses | 25↑55.5% | 16↓15.0% | 19↑0.7% | 19↑11.5% | 17 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 25↑55.5% | 16↓15.0% | 19↑0.7% | 19↑11.5% | 17 | |
| Other Expenses | 0.00↓100.0% | 6↑865270.6% | 0.00↑43.8% | 0.00 | 0.00 | |
| Operating Expenses | 163↑227.6% | 50↑27.0% | 39↓17.3% | 47↓26.5% | 65 | |
| Total Costs & Expenses | 163↑227.6% | 50↑27.0% | 39↓17.3% | 47↓26.5% | 65 | |
| Operating Results | ||||||
| Operating Income | -153↓205.9% | -50↓27.0% | -39↑17.1% | -47↑25.3% | -63 | |
| Depreciation & Amortization | 0.08↑138.8% | 0.04↓77.1% | 0.15↓26.0% | 0.21↓21.7% | 0.26 | |
| EBITDA | -150↓238.8% | -44↓12.9% | -39↑17.1% | -47↑25.3% | -63 | |
| EBIT | -150↓238.7% | -44↓12.6% | -39↑17.1% | -47↑25.3% | -63 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.69↑362.6% | 0.15↓93.7% | 2↑232.5% | 0.71↑3514.5% | 0.02 | |
| Interest Income | 3↑187.2% | 1↓57.9% | 2↑232.5% | 0.71↑3514.5% | 0.02 | |
| Interest Expense | 2↑156.5% | 0.85 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | -3↑49.5% | -6↓892900.2% | -0.00↓43.8% | -0.00 | 0.00 | |
| Other Income / Expenses | 0.69↓49.8% | 1↓42.2% | 2↑232.4% | 0.71↑3516.8% | 0.02 | |
| Income Before Tax | -152↓213.1% | -49↓31.5% | -37↑21.0% | -47↑26.4% | -63 | |
| Income Tax Expense | 2 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -154↓217.3% | -49↓31.5% | -37↑21.0% | -47↑26.4% | -63 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -154↓217.3% | -49↓31.5% | -37↑21.0% | -47↑26.4% | -63 | |
| Bottom-Line Net Income | -154↓217.3% | -49↓31.5% | -37↑21.0% | -47↑26.4% | -63 | |
| EPS (Basic) | -14.78↓955.7% | -1.40↓141.4% | -0.58↑34.8% | -0.89↑27.6% | -1.23 | |
| EPS (Diluted) | -14.78↓955.7% | -1.40↓141.4% | -0.58↑34.8% | -0.89↑27.6% | -1.23 | |
| Weighted Average Shares | 10↓46.6% | 20↓69.2% | 63↑20.6% | 53↑2.1% | 51 | |
| Weighted Average Diluted Shares | 10↓46.6% | 20↓69.2% | 63↑20.6% | 53↑2.1% | 51 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.